Prediction of Distant Metastases in Patients with Kidney Cancer Based on Gene Expression and Methylation Analysis

Author:

Apanovich Natalya1ORCID,Matveev Alexey2,Ivanova Natalia3,Burdennyy Alexey3ORCID,Apanovich Pavel1,Pronina Irina3ORCID,Filippova Elena3,Kazubskaya Tatiana2,Loginov Vitaly3,Braga Eleonora13ORCID,Alimov Andrei1ORCID

Affiliation:

1. Research Centre for Medical Genetics, 1 Moskvorechye St., Moscow 115522, Russia

2. Federal State Budgetary Institution (N.N. Blokhin National Medical Research Center of Oncology) of the Ministry of Health of the Russian Federation, 24 Kashirskoe Shosse, Moscow 115478, Russia

3. Institute of General Pathology and Pathophysiology, Baltijskaya St. 8, Moscow 125315, Russia

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive histological type of cancer in this location. Distant metastases are present in approximately 30% of patients at the time of first examination. Therefore, the ability to predict the occurrence of metastases in patients at early stages of the disease is an urgent task aimed at personalized treatment. Samples of tumor and paired histologically normal kidney tissue from patients with metastatic and non-metastatic ccRCC were studied. Gene expression was analyzed using real-time PCR. The level of gene methylation was evaluated using bisulfite conversion followed by quantitative methylation-specific PCR. Two groups of genes were analyzed in this study. The first group includes genes whose expression is significantly reduced during metastasis: CA9, NDUFA4L2, EGLN3, and BHLHE41 (p < 0.001, ROC analysis). The second group includes microRNA genes: MIR125B-1, MIR137, MIR375, MIR193A, and MIR34B/C, whose increased methylation levels are associated with the development of distant metastases (p = 0.002 to <0.001, ROC analysis). Based on the data obtained, a combined panel of genes was formed to identify patients whose tumors have a high metastatic potential. The panel can estimate the probability of metastasis with an accuracy of up to 92%.

Funder

Ministry of Science and Higher Education of the Russian Federation for Research Centre for Medical Genetics and for the Institute of General Pathology and Pathophysiology

Publisher

MDPI AG

Subject

Clinical Biochemistry

Reference84 articles.

1. Makino, T., Kadomoto, S., Izumi, K., and Mizokami, A. (2022). Epidemiology and Prevention of Renal Cell Carcinoma. Cancers, 14.

2. Ljungberg, B., Albiges, L., Bedke, J., Bex, A., Capitanio, U., Giles, R.H., Hora, M., Klatte, T., Marconi, L., and Powles, T. (2023, March 01). EAU Guidelines on Renal Cell Carcinoma; EAU Annual Congress Milan; 2023; ISBN 978-94-92671-19-6. Available online: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Renal-Cell-Carcinoma-2023.pdf.

3. Kaprin, A., Starinsky, V., and Shakhzadova, A. (2021, March 01). Malignant Neoplasms in Russia in 2020 (Morbidity and Mortality); Moscow; Russia; 2021; ISBN 978-5-85502-268-1. Available online: https://oncology-association.ru/wp-content/uploads/2021/11/zis-2020-elektronnaya-versiya.pdf.

4. The State of Oncology Care in Russia. Kidney Cancer (Morbidity, Mortality, Index of Accuracy, One-Year and Year-by-Year Mortality, Histological Structure). Part 1;Merabishvili;Onkourologiya,2021

5. Classification of Renal Cell Tumors—Current concepts and use of ancillary tests: Recommendations of the Brazilian Society of Pathology;Athanazio;Surg. Exp. Pathol.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3